Journal Article

Designing and implementing the IDEAL Study: A randomized clinical trial of APOE genotype disclosure for late‐onset Alzheimer's disease in an urban Latino population

Uhlmann, Wendy, Wetmore, John B., Rodriguez, Sophia, Abraído‐Lanza, Ana, Ferber, Rebecca, Blasco, Drew, Goldman, Jill, Ottman, Ruth, Diaz Caro, Daniela, Leu, Cheng‐Shiun, Cabán, María, Godinez, Jonathan D., Roberts, J. Scott, Chung, Wendy K., Lantigua, Rafael A., Camarillo, Itzel A., Siegel, Karolynn

2024

Overview

INTRODUCTION The Información de la Enfermedad de Alzheimer para Latinos (IDEAL) Study is a randomized clinical trial investigating the psychosocial, behavioral, and cognitive impacts of apolipoprotein E (APOE) genotype disclosure for late‐onset Alzheimer's disease (AD) among Latinos. METHODS We used address‐based sampling to recruit English‐ and Spanish‐speaking Latinos aged 40–64 living in northern Manhattan for a community‐based Baseline Survey about their knowledge and opinions about AD. Participants eligible for the clinical trial were invited to complete an Introductory Session, including AD and genetics education and informed consent, before undergoing genotyping for APOE. Participants were then randomized to learn their risk of AD by age 85 (range: 21%–55%) based on either Latino ethnicity and family history alone, or the same factors and their APOE genotype. Risk information is provided in a semi‐structured genetic counseling session. Psychological impacts, health‐related behavioral changes, and cognitive performance are evaluated 6 weeks, 9 months, and 15 months later via surveys and qualitative interviews. To promote cultural competence, study materials were developed by a multidisciplinary team including bilingual and bicultural staff, Latinx content experts, and genetic counselors. RESULTS We sent invitations to 91,433 households; 5542 (6.1%) responded, 2120 completed the Baseline Survey (78.5% online; 21.5% via computer‐assisted telephone interview), and 2087 were deemed eligible, yielding a response rate of 2.3%. Many participants expressed appreciation for the opportunity to contribute to AD research. We randomized 374 participants for the clinical trial. DISCUSSION We describe the study design, recruitment and retention strategies, and interventions employed in the IDEAL Study. Our design provides a framework for future studies using rigorous mixed methods. Our findings may facilitate the development of culturally‐sensitive educational materials about AD and genetic testing, as well as genetic counseling protocols, to improve coping and adjustment in response to receiving risk information. Highlights The Información de la Enfermedad de Alzheimer para Latinos (IDEAL) Study investigates apolipoprotein E (APOE) genotype disclosure among Latinos using mixed methods. We recruited adults 40–64 years of age without Alzheimer's disease (AD) for a community‐based survey and randomized trial. Trial participants receives AD risk estimates with or without APOE genotypes. Psychosocial, behavioral, and cognitive impacts are assessed over 15 months. Findings may inform AD educational materials and genetic counseling protocols.

• Publisher: John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
• Subject: Alzheimer's disease / Anxiety / APOE genotype disclosure / Apolipoproteins / behavioral / Bilingualism / clinical trial / Coping / Coronaviruses / Disease / Ethnicity / Family medical history / Genetic counseling / Genetic testing / Genotype & phenotype / Health risk assessment / Hispanic Americans / Households / Latino: Hispanic / Memory / memory test / mixed methods / Pandemics / psychosocial / Qualitative research / randomized / social implications